HSBC Holdings
VERA icon

HSBC Holdings’s Vera Therapeutics VERA Stock Holding History

HSBC Holdings’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-297,017
Closed -$8.63M – 3171
2025
Q3 		$8.63M Buy
+297,017
New +$6.87M ﹤0.01% 983
2025
Q1 		– Sell
-6,228
Closed -$264K – 3285
2024
Q4 		$264K Buy
+6,228
New +$276K ﹤0.01% 2569

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

HSBC Holdings's VERA Position: Q4 2025 in Review

HSBC Holdings sold out of Vera Therapeutics (VERA) in Q4 2025, closing a stake of 297,017 shares — an estimated $8.63M sold.

HSBC Holdings first reported a position in VERA in Q4 2024 and held it in 2 quarters. The position peaked at $8.63M in Q3 2025. 214 funds tracked by Wall St. Rank hold VERA as of Q4 2025.

  • HSBC Holdings reported no remaining Vera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 297,017 Vera Therapeutics shares in Q4 2025, an estimated $8.63M.
  • HSBC Holdings first reported a position in Vera Therapeutics in Q4 2024 and held it in 2 quarters.
  • HSBC Holdings's Vera Therapeutics position peaked at $8.63M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.